Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | GPR119 | Q8TDV5 | 8/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.36 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.36 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17006178 | 0.91 | USP2 (0.38) | USP2SMN1; SMN2GPR119TSHRALOX15 | |
| SCHEMBL17006179 | 0.91 | USP2 (0.38) | USP2SMN1; SMN2GPR119TSHRALOX15 | |
| SCHEMBL17022203 | 0.85 | GPR119 (0.36) | USP2SMN1; SMN2GPR119TSHRALOX15 | |
| SCHEMBL17019234 | 0.84 | USP2 (0.37) | USP2SMN1; SMN2GPR119TSHRALOX15 | |
| SCHEMBL17006209 | 0.84 | USP2 (0.43) | USP2SMN1; SMN2GPR119DDB1CRBN | |
| SCHEMBL17006221 | 0.83 | USP2 (0.40) | USP2SMN1; SMN2GPR119DDB1CRBN | |
| SCHEMBL17006104 | 0.81 | USP2 (0.43) | USP2SMN1; SMN2GPR119DDB1CRBN | |
| SCHEMBL25986202 | 0.81 | USP2 (0.45) | USP2SMN1; SMN2GPR119DDB1CRBN | |
| SCHEMBL17006159 | 0.80 | TSHR (0.42) | SMN1; SMN2GPR119TSHRALOX15ATM | |
| SCHEMBL17006158 | 0.80 | TSHR (0.42) | SMN1; SMN2GPR119TSHRALOX15ATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9273067-B2 | Pyrazolopyrimidine macrocycles as inhibitors of human immunodeficiency virus replication | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-03-01 | — | — | US | disclosed |
| US-20150232481-A1 | Pyrazolopyrimidine Macrocycles as Inhibitors of Human Immunodeficiency Virus Replication | VIIV HEALTHCARE UK (NO. 5) LIMITED (GB) | 2015-08-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150232481-A1 | Pyrazolopyrimidine Macrocycles as Inhibitors of Human Immunodeficiency Virus Replication | TYMP, EIF2AK2, MAVS | USP2 3824/4885SMN1; SMN2 3448/4885GPR119 2720/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.